Mechanism of inflammatory cancer-associated fibroblast-mediated drug resistance in colorectal cancer cells

doi:10.19401/j.cnki.1007-3639.2023.12.001

Abstract

Abstract:

Background and purpose: Colorectal cancer (CRC) is one of the common malignancies, but the mechanism by which it develops resistance to drug remains unclear. The tumor microenvironment (TME), especially cancer-associated fibroblast (CAF), plays an important role in the occurrence, development and drug resistance of tumors. This study aimed to investigate the effect of inflammatory cancer-associated fibroblasts (iCAF) on drug resistance in CRC cells and its possible mechanism. Methods: The primary CAFs were collected from CRC patients underwent surgery in Putuo Hospital, Shanghai University of Traditional Chinese Medicine from Aug. 2022 to Sep. 2022, and the primary cells were sorted according to the surface marker of CAF[approved by the Ethics Committee of Putuo Hospital Affiliated to Shanghai University of Traditional Chinese Medicine: PTEC-A-2023-5(S)-1], platelet derived growth factor receptor alpha (PDGFRA), to screen iCAF. Human intestinal fibroblast (HIF) and iCAF cells were cultured using serum-free medium to obtain conditioned medium. According to the treatment method, colon cancer cells were divided into control group (no treatment), experimental group 1(treated with HIF-CM) and experimental group 2 (treated with iCAF-CM). We observed the changes in the survival rate and apoptotic rate of CRC cells, the changes in protein and mRNA levels and the effect on the Wnt/β-catenin signaling pathway after stimulation with HIF-CM or iCAF-CM. Results: After iCAFs stimulation, the half inhibition concentration (IC₅₀) of CRC cells was higher compared with the control group and HIF-CM group (P<0.05). Compared with the control group and HIF-CM group, the apoptotic rate of tumor cells in iCAF-CM group decreased significantly, the expression of caspase-3 was decreased, and the expressions of Bcl-2, Bcl-xL and survivin were increased (P<0.05). The Wnt/β-catenin signaling pathway was activated in the iCAF-CM group. Conclusion: iCAFs can mediate drug resistance in CRC cells, and the mechanism is related to the activation of Wnt/β-catenin signaling pathway.

Key words: Colorectal cancer, Inflammatory cancer-associated fibroblasts, Drug resistance, Wnt/β-catenin signaling pathway

CLC Number:

CAI Jialuo, ZHU Ruiqiu, LI Sen, CAO Yijun, HUANG Fang. Mechanism of inflammatory cancer-associated fibroblast-mediated drug resistance in colorectal cancer cells[J]. China Oncology, 2023, 33(12): 1065-1072.

Figures/Tables 6

Fig. 1

Fig. 2

Fig. 3

Fig. 4

Fig. 5

Fig. 6

References 15

[1]	周昌明, 王泽洲, 郑莹. 2023年美国癌症数据解读及对中国癌症防治的启示[J]. 中国癌症杂志, 2023, 33(2): 117-125. doi: 10.19401/j.cnki.1007-3639.2023.02.004
	ZHOU C M, WANG Z Z, ZHENG Y. Interpretation of US cancer statistics 2023 and its implications for cancer prevention and treatment in China[J]. China Oncol, 2023, 33(2): 117-125.
[2]	NIKOLAOU M, PAVLOPOULOU A, GEORGAKILAS A G, et al. The challenge of drug resistance in cancer treatment: a current overview[J]. Clin Exp Metastasis, 2018, 35(4): 309-318. doi: 10.1007/s10585-018-9903-0
[3]	SUN Y. Tumor microenvironment and cancer therapy resistance[J]. Cancer Lett, 2016, 380(1): 205-215. doi: 10.1016/j.canlet.2015.07.044 pmid: 26272180
[4]	ELYADA E, BOLISETTY M, LAISE P, et al. Cross-species single-cell analysis of pancreatic ductal adenocarcinoma reveals antigen-presenting cancer-associated fibroblasts[J]. Cancer Discov, 2019, 9(8): 1102-1123. doi: 10.1158/2159-8290.CD-19-0094 pmid: 31197017
[5]	BU L K, BABA H, YASUDA T, et al. Functional diversity of cancer-associated fibroblasts in modulating drug resistance[J]. Cancer Sci, 2020, 111(10): 3468-3477. doi: 10.1111/cas.v111.10
[6]	YOSHIDA G J. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways[J]. J Exp Clin Cancer Res, 2020, 39(1): 112. doi: 10.1186/s13046-020-01611-0 pmid: 32546182
[7]	CHEN Z H, ZHOU L J, LIU L L, et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma[J]. Nat Commun, 2020, 11(1): 5077. doi: 10.1038/s41467-020-18916-5 pmid: 33033240
[8]	SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.v71.3
[9]	KADEL D, ZHANG Y, SUN H R, et al. Current perspectives of cancer-associated fibroblast in therapeutic resistance: potential mechanism and future strategy[J]. Cell Biol Toxicol, 2019, 35(5): 407-421. doi: 10.1007/s10565-019-09461-z pmid: 30680600
[10]	SAHAI E, ASTSATUROV I, CUKIERMAN E, et al. A framework for advancing our understanding of cancer-associated fibroblasts[J]. Nat Rev Cancer, 2020, 20(3): 174-186. doi: 10.1038/s41568-019-0238-1 pmid: 31980749
[11]	李学勤, 徐克. 肿瘤相关成纤维细胞促进肿瘤侵袭转移的作用机制[J]. 中国生物化学与分子生物学报, 2019, 35(4): 386-392. doi: 10.13865/j.cnki.cjbmb.2019.04.06
	LI X Q, XU K. Mechanism of cancer-associated fibroblasts promoting tumor metastasis and invasion[J]. Chin J Biochem Mol Biol, 2019, 35(4): 386-392.
[12]	HU J L, WANG W, LAN X L, et al. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer[J]. Mol Cancer, 2019, 18(1): 91. doi: 10.1186/s12943-019-1019-x pmid: 31064356
[13]	ZHANG F, CUI J Y, GAO H F, et al. Cancer-associated fibroblasts induce epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer via CXCL12/CXCR4 axis[J]. Future Oncol, 2020, 16(32): 2619-2633. doi: 10.2217/fon-2020-0095
[14]	JUNG Y S, PARK J I. Wnt signaling in cancer: therapeutic targeting of Wnt signaling beyond β-catenin and the destruction complex[J]. Exp Mol Med, 2020, 52(2): 183-191. doi: 10.1038/s12276-020-0380-6
[15]	FERRARI N, RANFTL R, CHICHEROVA I, et al. Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts[J]. Nat Commun, 2019, 10(1): 130. doi: 10.1038/s41467-018-07987-0 pmid: 30631061